Pentagon to study military biotech enhancements—with minimal public oversight
H.R. 5193 — To direct the Chairman of the Joint Chiefs of Staff to conduct a feasibility study on incorporating militarily-relevant applications of emerging biotechnology into wargaming exercises, and for other purposes. · Filed by Ro Khanna (D-CA) · 2 cosponsors · Introduced Sep 8, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the Chairman of the Joint Chiefs of Staff to study whether the U.S. military should incorporate emerging biotechnology applications—such as performance-enhancing drugs, biotech-enabled materials, and adversary biotech tactics—into its war-game exercises. The study must be completed within 180 days and delivered to Congress, with recommendations on how to update wargaming to reflect real-world biotech threats and capabilities.
Why we flagged it
The bill is a directive for a feasibility study on integrating emerging biotechnology into military wargaming. It is not legislation that directly mandates biotech programs, but rather a fact-finding exercise that could inform future military doctrine and procurement decisions around biotechnology applications.
What the text implies
- The study may create institutional momentum toward military human-enhancement programs (cognitive/physical performance biotech) without explicit congressional authorization or public debate on ethical, safety, or consent implications for service members.
- Framing adversary biotech capabilities as a 'wargaming' problem may accelerate U.S. biotech weapons research or dual-use biotechnology development under the guise of defensive preparedness.
The full analysis lists 4 implications of this text.
Who stands to gain
pharmaceutical companies (biotech-focused); defense contractors with biotech divisions; military research institutions (DARPA, service labs)